Country: Canada
Language: English
Source: Health Canada
LISINOPRIL (LISINOPRIL DIHYDRATE); HYDROCHLOROTHIAZIDE
TEVA CANADA LIMITED
C09BA03
LISINOPRIL AND DIURETICS
10MG; 12.5MG
TABLET
LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG; HYDROCHLOROTHIAZIDE 12.5MG
ORAL
30/100
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0222417003; AHFS:
APPROVED
2010-12-08
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-LISINOPRIL/HCTZ (TYPE Z) Lisinopril and Hydrochlorothiazide Tablets Tablets, 10 mg / 12.5 mg, 20 mg / 12.5 mg and 20 mg / 25 mg, Oral Angiotensin Converting Enzyme Inhibitor / Diuretic (C09BA03) Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada M1B 2K9 www.tevacanada.com Submission Control Number: 262161 Date of Initial Authorization: November 21, 2007 Date of Revision: August 11, 2022 TEVA-LISINOPRIL/HCTZ (TYPE Z) Page 2 of 63 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions – Ophthalmologic 08/2022 7 Warnings and Precautions – Carcinogenesis and Mutagenesis 08/2022 7 Warnings and Precautions – Skin 08/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .............................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION........................................................................ 4 1 INDICATIONS ......................................................................................................................... 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS............................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ....................................................................... 5 4 DOSAGE AND ADMINISTRATION ........................................................................................... 5 4.1 Dosing Considerations .................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ................................................. Read the complete document